After seven patient deaths, ADC gets partial hold and decides to stop Zynlonta trial
ADC Therapeutics says it plans to stop a mid-stage study of Zynlonta in unfit or frail patients with large B cell lymphoma.
The Thursday afternoon …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
